NIFTY23,869.601.26%
SENSEX76,564.921.42%
BANKNIFTY55,912.100.70%
NIFTY IT28,575.405.14%
PHARMA22,678.451.34%
AUTO25,621.800.80%
FMCG50,624.751.01%
METAL12,713.150.57%
REALTY777.001.48%
ENERGY39,670.000.82%
NIFTY23,869.601.26%
SENSEX76,564.921.42%
BANKNIFTY55,912.100.70%
NIFTY IT28,575.405.14%
PHARMA22,678.451.34%
AUTO25,621.800.80%
FMCG50,624.751.01%
METAL12,713.150.57%
REALTY777.001.48%
ENERGY39,670.000.82%

ICICI Securities Makes Healthcare Sector Earnings Predictions for Q4 2026

ICICI Securities has released its fourth quarter earnings estimates for the Healthcare sector, highlighting potential growth for Metropolis. According to the brokerage house, Metropolis is expected to report a net profit of Rs. 60.5 crore, representing a year-over-year increase of 34.8%. This growth also surpasses the previous quarter, with a gain of 25.8% quarter-over-quarter.

ICICI Securities forecasts a notable increase in Net Sales for Metropolis, projecting a 23.2% year-over-year growth to Rs. 425.4 crore. This growth rate is also reflected in the previous quarter, with a 4.8% quarter-over-quarter increase. The expected growth in Net Sales is a key indicator of the company's financial performance.

In addition to Net Sales growth, ICICI Securities predicts a significant rise in Earnings before interest, tax, depreciation and amortisation (EBITDA) for Metropolis. The brokerage house expects EBITDA to increase by 35.8% year-over-year to Rs. 113.2 crore, and by 19.3% quarter-over-quarter. This growth in EBITDA is a crucial metric for evaluating the company's profitability and operational efficiency.

Read also: Thyrocare Expects 84.9% Year-on-Year Increase in Q4 Net Profit

MetricQ4 2025Q4 2026 (Est.)Y-o-Y GrowthQ-o-Q Growth
Net Profit (Rs. Crore)-60.534.8%25.8%
Net Sales (Rs. Crore)-425.423.2%4.8%
EBITDA (Rs. Crore)-113.235.8%19.3%

Investor Takeaway

Metropolis is expected to report a 34.8% year-over-year increase in profit to Rs. 60.5 crore.

IPOScanner Logo

IPOScanner helps investors track upcoming, live and past IPOs in one place with GMP, subscription, allotment status and listing performance insights.

About IPO Scanner

IPOScanner is built for investors who want a clear view of every IPO opportunity in one place. From upcoming issues to live subscription data, allotment updates and listing performance, we bring together the key details you need to track the primary market.

Our tools are designed to be simple, fast and investor-friendly so you can focus on evaluating businesses instead of opening multiple tabs and websites for basic information.

Details of client bank account
For any query / feedback / clarifications, email at
help@iposcanner.ai.

Please read all offer documents and risk disclosures carefully before investing. IPOScanner does not provide investment advice and information on this site should not be treated as a recommendation to apply for any IPO.

© 2026 IPO Scanner. All rights reserved.